Name | Number of supported studies | Average coverage | |
---|---|---|---|
fibroblast | 26 studies | 27% ± 9% | |
smooth muscle cell | 22 studies | 28% ± 10% | |
pericyte | 22 studies | 26% ± 8% | |
endothelial cell | 18 studies | 26% ± 10% | |
endothelial cell of lymphatic vessel | 12 studies | 25% ± 6% | |
ciliated cell | 11 studies | 24% ± 5% | |
myofibroblast cell | 11 studies | 31% ± 14% | |
connective tissue cell | 10 studies | 27% ± 10% | |
adipocyte | 10 studies | 46% ± 9% | |
type I pneumocyte | 9 studies | 32% ± 10% | |
epithelial cell | 7 studies | 28% ± 9% | |
podocyte | 5 studies | 37% ± 9% | |
cardiac muscle cell | 5 studies | 33% ± 8% | |
astrocyte | 5 studies | 33% ± 9% | |
mesothelial cell | 4 studies | 31% ± 10% | |
basal cell | 4 studies | 29% ± 10% | |
type II pneumocyte | 4 studies | 22% ± 4% | |
goblet cell | 4 studies | 25% ± 9% | |
muscle cell | 3 studies | 38% ± 15% | |
GABAergic neuron | 3 studies | 42% ± 2% | |
glutamatergic neuron | 3 studies | 39% ± 4% | |
oligodendrocyte precursor cell | 3 studies | 21% ± 4% | |
adventitial cell | 3 studies | 20% ± 1% | |
club cell | 3 studies | 21% ± 5% | |
respiratory goblet cell | 3 studies | 23% ± 7% | |
transit amplifying cell | 3 studies | 28% ± 15% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
breast | 100% | 9219.25 | 459 / 459 | 100% | 38.24 | 1117 / 1118 |
ovary | 100% | 6628.27 | 180 / 180 | 100% | 24.13 | 428 / 430 |
prostate | 100% | 8497.69 | 244 / 245 | 100% | 37.93 | 501 / 502 |
lung | 100% | 6225.65 | 576 / 578 | 99% | 25.25 | 1148 / 1155 |
intestine | 99% | 13007.67 | 955 / 966 | 100% | 25.55 | 526 / 527 |
uterus | 100% | 13395.62 | 170 / 170 | 98% | 24.69 | 452 / 459 |
esophagus | 98% | 12817.54 | 1420 / 1445 | 100% | 24.98 | 183 / 183 |
bladder | 100% | 11932.24 | 21 / 21 | 98% | 21.63 | 494 / 504 |
pancreas | 98% | 3584.39 | 323 / 328 | 99% | 34.19 | 177 / 178 |
kidney | 99% | 4250.73 | 88 / 89 | 99% | 28.56 | 891 / 901 |
thymus | 99% | 4124.78 | 648 / 653 | 96% | 20.11 | 582 / 605 |
stomach | 95% | 8119.46 | 340 / 359 | 100% | 29.94 | 285 / 286 |
skin | 89% | 6418.09 | 1617 / 1809 | 100% | 50.35 | 472 / 472 |
adrenal gland | 94% | 3179.51 | 242 / 258 | 87% | 13.80 | 199 / 230 |
brain | 61% | 1484.82 | 1606 / 2642 | 93% | 18.40 | 656 / 705 |
liver | 40% | 906.11 | 91 / 226 | 78% | 9.66 | 318 / 406 |
adipose | 100% | 11615.87 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 10867.11 | 1335 / 1335 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 46.59 | 80 / 80 |
tonsil | 0% | 0 | 0 / 0 | 100% | 15.47 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 7.49 | 1 / 1 |
heart | 92% | 4711.03 | 793 / 861 | 0% | 0 | 0 / 0 |
spleen | 68% | 1778.46 | 165 / 241 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 31% | 2.13 | 9 / 29 |
muscle | 16% | 376.59 | 132 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 0% | 2.32 | 1 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0060271 | Biological process | cilium assembly |
GO_0003148 | Biological process | outflow tract septum morphogenesis |
GO_0007163 | Biological process | establishment or maintenance of cell polarity |
GO_0034113 | Biological process | heterotypic cell-cell adhesion |
GO_0002040 | Biological process | sprouting angiogenesis |
GO_0070252 | Biological process | actin-mediated cell contraction |
GO_0030036 | Biological process | actin cytoskeleton organization |
GO_0034446 | Biological process | substrate adhesion-dependent cell spreading |
GO_0050821 | Biological process | protein stabilization |
GO_0071670 | Biological process | smooth muscle cell chemotaxis |
GO_0008360 | Biological process | regulation of cell shape |
GO_0005886 | Cellular component | plasma membrane |
GO_0030018 | Cellular component | Z disc |
GO_0005925 | Cellular component | focal adhesion |
GO_0015629 | Cellular component | actin cytoskeleton |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0030027 | Cellular component | lamellipodium |
GO_0005634 | Cellular component | nucleus |
GO_0004860 | Molecular function | protein kinase inhibitor activity |
GO_0045296 | Molecular function | cadherin binding |
GO_0005515 | Molecular function | protein binding |
GO_0003779 | Molecular function | actin binding |
Gene name | PARVA |
Protein name | Parvin alpha Alpha-parvin (Actopaxin) (CH-ILKBP) (Calponin-like integrin-linked kinase-binding protein) (Matrix-remodeling-associated protein 2) |
Synonyms | MXRA2 |
Description | FUNCTION: Plays a role in sarcomere organization and in smooth muscle cell contraction. Required for normal development of the embryonic cardiovascular system, and for normal septation of the heart outflow tract. Plays a role in sprouting angiogenesis and is required for normal adhesion of vascular smooth muscle cells to endothelial cells during blood vessel development (By similarity). Plays a role in the reorganization of the actin cytoskeleton, formation of lamellipodia and ciliogenesis. Plays a role in the establishment of cell polarity, cell adhesion, cell spreading, and directed cell migration. . |
Accessions | Q9NVD7 ENST00000334956.15 [Q9NVD7-1] ENST00000528916.1 E9PS97 |